



DR MONICA FUNG (Orcid ID : 0000-0002-1725-5259)

TIMOTHY HENRICH (Orcid ID : 0000-0002-6684-0622)

DR JENNIFER M BABIK (Orcid ID : 0000-0001-6914-4959)

Article type : Case Report

Title: Treatment of Immunocompromised COVID-19 patients with Convalescent Plasma

Authors:

Monica Fung, MD, MPH,¹ Ashok Nambiar, MD,² Suchi Pandey, MD,³ J. Matthew Aldrich, MD,⁴ Justin Teraoka, BS,¹ Christopher Freise, MD,⁵ John Roberts, MD,⁵ Sindhu Chandran, MD,⁶ Steven R. Hays, MD,⁷ Emma Bainbridge, MD,¹ Catherine DeVoe, MD,¹ Annelys Roque Gardner, MD,¹ Deborah Yokoe, MD,¹ Timothy J. Henrich, MD,¹ Jennifer M. Babik, MD, PhD,¹ Peter Chin-Hong, MD¹

ORCID:

Monica Fung (0000-0002-1725-5259)

Jennifer Babik (0000-0001-6914-4959)

Sindhu Chandran (0000-0003-4547-3381)

Affiliations:

¹ Division of Infectious Disease, Department of Medicine, University of California San Francisco, San Francisco, USA

² Department of Laboratory Medicine, University of California San Francisco, San Francisco, USA

³ Department of Pathology, Stanford University School of Medicine, Palo Alto, CA

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the [Version of Record](#). Please cite this article as [doi: 10.1111/TID.13477](https://doi.org/10.1111/TID.13477)

This article is protected by copyright. All rights reserved

⁴ Department of Anesthesia and Perioperative Care, University of California San Francisco, San Francisco, USA

⁵ Division of Transplant Surgery, Department of Surgery, University of California San Francisco, San Francisco, USA

⁶ Division of Nephrology, Department of Medicine, University of California San Francisco, San Francisco, USA

⁷ Division of Pulmonary, Critical Care, Allergy and Sleep Medicine, Department of Medicine, University of California San Francisco, San Francisco, USA

Corresponding author:

Monica Fung
monica.fung@ucsf.edu

Running Title: CCP in transplant patients

Key words: COVID-19, convalescent plasma, transplant, immunocompromised

Abbreviations:

SARS-CoV-2: Severe acute respiratory syndrome coronavirus 2

COVID-19: Coronavirus disease 2019

SOT: solid organ transplant

ABSTRACT

Immunosuppressed patients such as solid organ transplant and hematologic malignancy patients appear to be at increased risk for morbidity and mortality due to coronavirus disease 2019 (COVID-19) caused by SARS coronavirus 2 (SARS-CoV-2). Convalescent plasma, a method of passive immunization that has been applied to prior viral pandemics, holds promise as a potential treatment for COVID-19. Immunocompromised patients may experience more benefit from convalescent plasma given underlying deficits in B and T cell immunity as well as contraindications to antiviral and immunomodulatory therapy. We describe our institutional experience with four immunosuppressed patients (two kidney transplant recipients, one lung transplant recipient, and one chronic myelogenous leukemia patient) treated with COVID-19 convalescent plasma through Expanded Access Program (NCT 04338360). All patients clinically improved after administration (two fully recovered and two discharged to skilled nursing facilities) and none experienced a transfusion reaction. We also report characteristics of convalescent plasma product from a local blood center including positive SARS-CoV-2 IgG and negative SARS-CoV-2 PCR in all samples tested. This preliminary evidence suggest that convalescent plasma may be safe among immunosuppressed patients with COVID-19, and emphasizes the need for further data on efficacy of convalescent plasma as either primary or adjunctive therapy for COVID-19.

INTRODUCTION

The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to a global pandemic with over 25 million reported cases and over 850,000 deaths.^{1,2} Clinical coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2 varies from asymptomatic infection to critical illness.^{3,4} Some groups of immunocompromised patients appear to be at increased risk for severe COVID-19 disease. The mortality rate among solid organ transplant (SOT) recipients is reported to be as high as 60%,⁵⁻¹¹ and mortality in hematologic malignancy patients is similarly high.¹²

There are currently limited COVID-19 therapies with proven efficacy. Early evidence suggests that the antiviral remdesivir can shorten time to recovery¹³ and dexamethasone can reduce 28-day mortality.¹⁴ Convalescent plasma (CP) is a passive immunization strategy used in the treatment of infectious diseases since the 1900s. CP is obtained via apheresis of infection survivors who have evidence of antibody production. The goal of therapy when applied early in infection is to neutralize virus and minimize resulting inflammatory cascade. CP has been described to reduce mortality, decrease complications, and speed viral clearance of infections including the influenza pandemic of 1918,¹⁵ SARS,¹⁶ influenza H1N1,¹⁷ and Ebola.¹⁸

While there is increasing data on the safety and potential benefit of CP in patients with COVID-19,^{19,20} experience with this therapeutic among immunocompromised patients is limited. These populations may benefit more from CP compared to immunocompetent patients due to their inability to mount appropriate cellular and humoral immune responses to the virus.²¹ Here, we report our institutional experience with four immunocompromised patients, three SOT recipients and one hematologic malignancy patient, with COVID-19 treated with CP.

MATERIALS AND METHODS

Study Subjects and Setting

Subjects

Hospitalized SOT and hematologic malignancy patients cared for at the University of California San Francisco (UCSF) were enrolled in the Expanded Access Program (EAP) for Convalescent Plasma

(NCT 04338360, UCSF IRB #20-30657). Included subjects were ≥ 18 years, with laboratory-confirmed SARS-CoV-2 infection, and with or at risk of progression to severe or life-threatening COVID-19 disease. Severe disease was defined as the presence of dyspnea, respiratory rate ≥ 30 /min, oxygen saturation $\leq 93\%$, $\text{PaO}_2/\text{FiO}_2 < 300$, or pulmonary infiltrates. Life-threatening disease was defined by the presence of respiratory failure, septic shock, or multiple organ dysfunction/failure. Data on demographics, medical history, clinical results, treatment, and outcomes were extracted from the electronic medical record as approved under UCSF IRB #20-30629.

COVID-19 diagnostic testing

Patients were diagnosed with COVID-19 using RNA testing of nasopharyngeal (NP) or pooled nasopharyngeal/oropharyngeal (NP/OP) swab samples performed using a real-time reverse transcriptase-polymerase chain reaction (PCR) assay.²² SARS-CoV-2 IgG was available but not conducted routinely.

Therapeutic approach

During the study period, our institutional treatment approach was to enroll patients with severe or life-threatening COVID-19 disease into clinical trials, if possible. The main trial has been the National Institute of Allergy and Infectious Diseases Adaptive COVID-19 Treatment Trial (ACTT), a randomized controlled trial of remdesivir (NCT 04280705). Patients who did not qualify or consent for the study were considered for remdesivir through either the EUA or EAP program. They were also considered for EAP CP. All admitted COVID-19 patients were provided aggressive supportive care.

Convalescent plasma

Donor selection and qualification

All CP units transfused were collected per U.S. Food & Drug Administration guidance from donors with confirmed COVID-19 diagnosis based on positive PCR. If donating within 14-28 days post-resolution of symptoms, a negative PCR was required prior to donation. If > 28 days post-resolution of symptoms, repeat PCR was not required.

Collection and storage

CP was collected using standard apheresis methods and stored at -18°C within 8 hours of collection. Frozen units from Stanford Blood Center (SBC) and the American Red Cross (ARC) were shipped to

UCSF using validated coolers. Units were stored in a freezer at UCSF and when ready to use, removed and placed in a plasma thawer.

Donor CP samples from SBC were tested for antibodies against the receptor binding domain of SARS-CoV-2 spike protein using a validated laboratory-developed enzyme-linked immunosorbent assay (cut-off of 0.30 optical density). Binding titers were performed using the same assay at 1:100, 1:200, and 1:400 dilutions. A research PCR test targeting the SARS-CoV-2 *envelope* gene was also performed in EDTA plasma mini pools of 6 individuals (Stanford IRB#55550). Donor CP sample from ARC did not have PCR or antibody titers done.

Administration

In accordance with EAP program, one unit (approximately 200mL) of ABO-compatible CP was administered at a rate of 100mL/hour using standard blood administration procedures.

CASE SERIES

Case 1

A 44-year-old African-American man with deceased donor renal transplant for IgA nephropathy 19 years prior to presentation and hypertension presented to an outside institution 6 days after onset of fever, cough, dyspnea, and diarrhea and was diagnosed with COVID-19 by PCR (**Figure 1A**).

Maintenance immunosuppression consisted of mycophenolate, tacrolimus, and prednisone. Chest X-ray demonstrated patchy left lower lobe infiltrate and he received hydroxychloroquine (days 6-20), lopinavir/ritonavir (days 13-18), tocilizumab (days 12-13), methylprednisolone (days 17-20), and broad-spectrum antibiotics. On day 20 of illness, he was intubated and transferred to our center.

Hydroxychloroquine and steroids were discontinued, mycophenolate was held, and patient received CP on day 27 for life-threatening COVID-19. The patient did not qualify for ACTT-1 or EAP remdesivir due to acute kidney injury requiring hemodialysis. His course was complicated by right common femoral vein thrombosis (day 23) requiring anticoagulation then inferior vena cava filter placement, *Klebsiella* ventilator-associated pneumonia (day 24), gastrointestinal bleed (day 25), and candidemia (day 41). He underwent tracheostomy on day 50. On day 73 of illness, the patient was on room air and discharged to long-term acute care facility.

Case 2

A 44-year-old Hispanic male who underwent deceased donor renal transplant for end-stage renal disease secondary to hypertension 16 months prior presented asymptotically to the emergency department after exposure to roommate with COVID-19 (**Figure 1B**). Maintenance immunosuppression consisted of mycophenolate, tacrolimus, and prednisone. On initial asymptomatic presentation, PCR testing was positive and chest X-ray demonstrated bilateral patchy opacities, and was discharged home. Two days later, he developed dyspnea, dry cough, and diarrhea and represented for care. On admission, chest X-ray demonstrated bilateral patchy opacities and he required supplemental oxygen via non-rebreather. In the ICU, oxygen requirement reached a maximum of 10 liters per minute via high-flow nasal cannula. Tacrolimus and mycophenolate were held. ACTT was not enrolling during the patient's hospitalization, and he did not qualify for EAP remdesivir (not intubated). CP was administered on day 4 for severe COVID-19 disease. On day 9, the patient was oxygenating well on room air and discharged home. During telehealth visit on day 15, the patient was feeling well without symptoms.

Case 3

A 65-year-old Caucasian female with interstitial lung disease associated with Sjögren's syndrome who underwent bilateral lung transplant 9 months prior presented with two days of dyspnea on exertion, cough, sore throat and malaise (**Figure 1C**). She received induction with basiliximab, and was on maintenance immunosuppression with mycophenolate, tacrolimus, and prednisone. Chest X-ray demonstrated increased patchy left mid lung and retrocardiac consolidation and she required supplemental oxygen via nasal cannula for comfort (maximum 2 liters). Mycophenolate was held, and the patient received EUA remdesivir on day 4 of illness without significant clinical change, followed by CP on day 8 for severe COVID-19 disease. The patient was discharged home on day 10. During telehealth visit on day 17, the patient was feeling well without symptoms.

Case 4

62-year-old Hispanic male with CML on dasatinib, stage IV chronic kidney disease, hypertension, and poorly controlled diabetes (**Figure 1D**). He presented with two days of fatigue, diarrhea, and anorexia. On presentation, patient was afebrile but developed rapidly progressive hypoxemia requiring oxygen administered via high-flow nasal cannula. Computed tomography of the chest demonstrated bilateral peribronchovascular groundglass opacities and peripheral nodular

consolidation. Patient did not qualify for EAP remdesivir due to renal failure, and CP was administered on day 3 of illness for life-threatening COVID-19 disease. The patient was subsequently intubated (day 7), required continuous renal replacement therapy (day 12), with course complicated by shock of unclear etiology (day 15) and severe autonomic instability with systolic blood pressure ranges from 70-300 for which extensive work-up (toxicology consultation, CT, MRI, and EEG) was negative. The patient was extubated on day 41, and discharged to skilled nursing facility with no oxygen requirement on day 61.

CONVALESCENT PLASMA

CP was supplied by SBC for three patients (Cases 1, 2, and 4) and ARC for one patient (Case 3). CP from SBC was collected from donors who had confirmed COVID-19 by PCR testing. All SBC CP units were positive for IgG against the SARS-CoV-2 receptor binding domain protein and negative for SARS-CoV-2 PCR. **Table 1** provides information on binding titer, and samples have been retained to perform neutralizing antibody titers as required by the EAP.

DISCUSSION

We report our institutional experience with CP for the treatment of COVID-19 in four immunocompromised patients, including two renal transplant recipients, one lung transplant recipient, and one hematologic malignancy patient.

Increasing data indicates that CP is safe among patients with COVID-19, with <1% rate of transfusion reaction and thrombosis, and ~3% rate of cardiac events.²³ However, clear data on clinical benefit is lacking. A randomized controlled trial in China of 103 patients suggested a trend towards improvement (HR 1.4, p=0.26), particularly among patients with severe disease (HR 2.15, p=0.03).¹⁹ However, results were limited by lack of target enrollment and also confounded by variations in therapy. Another study from Texas reporting 25 patients with severe and/or life-threatening COVID-19 treated with CP found that 76% experienced at least 1-point improvement in WHO ordinal scale in the 14 days post-transfusion.²⁰ Other smaller case series predominantly from China²⁴⁻²⁸ document improvement in clinical, radiologic, and virologic COVID-19 parameters after CP administration including among elderly²⁹ and pregnant^{24,30} patients.

Although immunocompromised SOT patients can develop IgG response to SARS-CoV-2,³¹ their underlying functional deficits in B and T cell immunity²¹ may make them a population that experiences particular benefit from passive immunization from CP. In a prior report of three kidney transplant recipients with COVID-19 who received CP, all three recovered and exhibited positive SARS-CoV-2 IgG (no pre-transfusion baseline), though notably one patient experienced acute dyspnea after CP transfusion.³² The patients we report received CP at a median of 5.5 days from COVID-19 symptom onset, and none experienced any reactions to CP transfusion. Two patients received other antiviral or immunomodulatory therapy in addition to CP (Cases 1 and 3). All patients were clinically improving at the time of this report, with two discharged home and fully recovered (Cases 2 and 3) and two discharged to skilled nursing facilities (Cases 1 and 4). Our results represent preliminary evidence that CP may be safe for immunosuppressed patients.

This study has several limitations. As a small case series, we are unable to draw clear conclusions about the therapeutic efficacy of CP. Patients varied significantly with regards to COVID-19 disease severity and timecourse at the time of CP administration, and received potential confounding COVID-19 therapies.

Despite recent EUA for CCP,³³ larger randomized studies remain crucial to understand the role of CP in the treatment of COVID-19 and which, if any, subgroups (degree of immunosuppression, comorbidities, infection severity) of immunocompromised patients would benefit. There remains a significant gap in knowledge about the therapeutic mechanism of CP, characteristics predictive of efficacy such as titer of neutralizing antibodies, as well as potential downstream effects such as attenuated humoral immunity. Furthermore, CP donation and supply chains need to be further optimized at the local and national level. For the transplant community, it is worth examining whether the existing infrastructure for living donation could be leveraged to serve as a source of CP during this critical period.

In summary, there is currently limited evidence on both safety and efficacy of CP among immunosuppressed COVID-19 patients. We report our experience with three SOT and one hematologic malignancy patient with COVID-19 treated with CP, all of whom are clinically improving after administration and did not experience any transfusion reactions. Additional research is urgently

needed to better understand and optimize CP for the treatment of COVID-19 among immunosuppressed patients.

Accepted Article

ACKNOWLEDGEMENTS / FUNDING

This study was supported in part by a US Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) contract 75A50120C00096 (M.J. Joyner, PI).

Accepted Article

DISCLOSURE

PCH is a site investigator for convalescent plasma EAP. The remaining authors have no conflicts of interest to disclose.

Accepted Article

FIGURE LEGENDS

Figure 1. Clinical course of four immunosuppressed COVID-19 patients treated with convalescent plasma. Abbreviations: CXR, chest X-ray; HCQ, hydroxychloroquine; ICU, intensive care unit; HFNC, high-flow nasal cannula; VAP, ventilator-associated pneumonia; GIB, gastrointestinal bleed; LTAC, long-term acute care facility; CT, computed tomography; ED, emergency department; CTX, ceftriaxone; azithro, azithromycin; Abx, antibiotics; EUA, emergency use authorization; 2L, 2 liters; CRRT, continuous renal replacement therapy; SNF: skilled nursing facility

REFERENCES

1. World Health Organization. WHO statement regarding cluster of pneumonia cases in Wuhan, China. <https://www.who.int/china/news/detail/09-01-2020-who-statement-regarding-cluster-of-pneumonia-cases-in-wuhan-china>. Published 2019. Accessed August 4, 2020.
2. Dong E, Du H, Gardner L. An interactive web-based dashboard to track COVID-19 in real time. *Lancet Infect Dis*. February 2020. doi:10.1016/S1473-3099(20)30120-1
3. Guan W-J, Ni Z-Y, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med*. February 2020. doi:10.1056/NEJMoa2002032
4. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *JAMA*. February 2020. doi:10.1001/jama.2020.2648
5. Nair V, Jandovitz N, Hirsch JS, et al. COVID-19 in kidney transplant recipients. *Am J Transplant*. April 2020:ajt.15967. doi:10.1111/ajt.15967
6. Akalin E, Azzi Y, Bartash R, et al. Covid-19 and Kidney Transplantation. *N Engl J Med*. April 2020:NEJMc2011117. doi:10.1056/NEJMc2011117
7. Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter. *Am J Transplant*. 2020:0-3. doi:10.1111/ajt.15941
8. Montagud-Marrahi E, Cofan F, Torregrosa J, et al. Preliminary data on outcomes of SARS-CoV-2 infection in a Spanish single centre cohort of kidney recipients. *Am J Transplant*. May 2020:ajt.15970. doi:10.1111/ajt.15970
9. Webb GJ, Moon AM, Barnes E, Barritt AS, Marjot T. Determining risk factors for mortality in liver transplant patients with COVID-19. *Lancet Gastroenterol Hepatol*. 2020;1253(20):30125. doi:10.1016/S2468-1253(20)30125-4
10. Alberici F, Delbarba E, Manenti C, et al. A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia. *Kidney Int*. 2020:1-6. doi:10.1016/j.kint.2020.04.002
11. Fernández-Ruiz M, Andrés A, Loinaz C, et al. COVID-19 in solid organ transplant recipients: a single-center case series from Spain. *Am J Transplant*. 2020:0-3. doi:10.1111/ajt.15929
12. He W, Chen L, Chen L, et al. COVID-19 in persons with haematological cancers. *Leukemia*. 2020. doi:10.1038/s41375-020-0836-7
13. Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 —

- Preliminary Report. *N Engl J Med*. May 2020:NEJMoa2007764. doi:10.1056/NEJMoa2007764
14. RECOVERY Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19 - Preliminary Report. *N Engl J Med*. July 2020. doi:10.1056/NEJMoa2021436
15. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med*. 2006;145(8):599-609. doi:10.7326/0003-4819-145-8-200610170-00139
16. Soo YOY, Cheng Y, Wong R, et al. Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clin Microbiol Infect*. 2004;10(7):676-678. doi:10.1111/j.1469-0691.2004.00956.x
17. Hung IF, To KK, Lee C-K, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis*. 2011;52(4):447-456. doi:10.1093/cid/ciq106
18. van Griensven J, Edwards T, de Lamballerie X, et al. Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea. *N Engl J Med*. 2016;374(1):33-42. doi:10.1056/NEJMoa1511812
19. Li L, Zhang W, Hu Y, et al. Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19. *JAMA*. June 2020. doi:10.1001/jama.2020.10044
20. Salazar E, Perez KK, Ashraf M, et al. Treatment of COVID-19 Patients with Convalescent Plasma. *Am J Pathol*. May 2020:2020.05.08.20095471. doi:10.1016/j.ajpath.2020.05.014
21. Fishman JA. Infection in Organ Transplantation. *Am J Transplant*. 2017;17(4):856-879. doi:10.1111/ajt.14208
22. Centers for Disease Control and Prevention (CDC). Real-Time RT-PCR Panel for Detection 2019-Novel Coronavirus.
23. Joyner MJ, Bruno KA, Klassen SA, et al. Safety Update. *Mayo Clin Proc*. 2020;95(9):1888-1897. doi:10.1016/j.mayocp.2020.06.028
24. Zhang B, Liu S, Tan T, et al. Treatment With Convalescent Plasma for Critically Ill Patients With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. *Chest*. 2020;(April):1-5. doi:10.1016/j.chest.2020.03.039
25. Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *JAMA*. 2020;323(16):1582. doi:10.1001/jama.2020.4783

- Accepted Article
26. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. *Proc Natl Acad Sci U S A*. 2020;117(17):9490-9496. doi:10.1073/pnas.2004168117
 27. Ye M, Fu D, Ren Y, et al. Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. *J Med Virol*. April 2020:0-1. doi:10.1002/jmv.25882
 28. Zeng Q-L, Yu Z-J, Gou J-J, et al. Effect of Convalescent Plasma Therapy on Viral Shedding and Survival in Patients With Coronavirus Disease 2019. *J Infect Dis*. April 2020:1-40. doi:10.1093/infdis/jiaa228
 29. Kong Y, Cai C, Ling L, et al. Successful treatment of a centenarian with coronavirus disease 2019 (COVID-19) using convalescent plasma. *Transfus Apher Sci*. 2020;(May):102820. doi:10.1016/j.transci.2020.102820
 30. Anderson J, Schauer J, Bryant S, Graves CR. The use of convalescent plasma therapy and remdesivir in the successful management of a critically ill obstetric patient with novel coronavirus 2019 infection: A case report. *Case Reports Women's Heal*. 2020;27:e00221. doi:10.1016/j.crwh.2020.e00221
 31. Fung M, Chiu CY, DeVoe C, et al. Clinical Outcomes and Serologic Response in Solid Organ Transplant Recipients with COVID-19: A Case Series from the United States. *Am J Transplant*. June 2020:ajt.16079. doi:10.1111/ajt.16079
 32. Naeem S, Gohh R, Bayliss G, et al. Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy. *Transpl Infect Dis*. August 2020:e13451. doi:10.1111/tid.13451
 33. Mahase E. Covid-19: US approves emergency use of convalescent plasma despite warnings over lack of evidence. *BMJ*. 2020;370:m3327. doi:10.1136/bmj.m3327

Author Contributions

MF and PCH conceived and designed the analysis. MF, AN, SP, JMA, JT collected the data. MF, AN, and PCH performed the analysis. MF wrote the paper. CF, JR, SC, SRH, EB, CD, ARG, DY, TJH, and JMB participated in the clinical care of the patient and provided significant edits to the manuscript.

Table 1. COVID-19 convalescent plasma characteristics

Case	Supplier	DONOR		PRODUCT		ADMINISTRATION			Reaction
		Evidence of prior COVID-19 infection	Days symptom free at donation	SARS-CoV2 IgG Result (OD)	SARS-CoV2 Titer	SARS-CoV2 RT-PCR	Infusion duration (minutes)	Volume (mL)	
1	Stanford	NP PCR	14-28	Positive (1.19)	>1:400	Negative	146	214	No
2	Stanford	NP PCR	>28	Positive (1.63)	>1:400	Negative	124	207	No
3	American Red Cross	Not documented	>28	Not done	Not done	Not done	101	208	No
4	Stanford	NP PCR	>28	Positive (0.74)	>1:400	Negative	120*	206	No

* estimated infusion time

Abbreviations: NP PCR, nasopharyngeal PCR; OD, optical density

